$9.13 -0.2 -1.8%
Last Trade - 26/02/21
| Market Cap | £343.7m |
| Enterprise Value | £143.2m |
| Revenue | £n/a |
| Position in Universe | th / 6718 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. The Company is developing ensifentrine, the treatment for respiratory disease. Ensifentrine is an inhaled therapy that acts as both a bronchodilator and an anti-inflammatory agent in one compound. In addition to nebulized ensifentrine, the Company has developed dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI) formulations of ensifentrine for less severe patients. The Company’s subsidiaries include Verona Pharma Inc. and Rhinopharma Limited.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | February 24, 2005 |
| Public Since | March 30, 2005 |
| No. of Shareholders: | n/a |
| No. of Employees: | 22 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Market |
| Shares in Issue | 51,784,787 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Riverside 3 More London Place, LONDON, SE1 2RE, United Kingdom |
| Web | http://www.veronapharma.com/ |
| Phone | +44 20 32834200 |
| Contact | () |
| Auditors | PricewaterhouseCoopers LLP |
As of 26/02/21, shares in Verona Pharma are trading at $9.13, giving the company a market capitalisation of £343.7m. This share price information is delayed by 15 minutes.
Shares in Verona Pharma are currently trading at $9.13 and the price has moved by 37.98% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Verona Pharma price has moved by 4.71% over the past year.
There are no analysts currently covering Verona Pharma.
Verona Pharma is scheduled to issue upcoming financial results on the following dates:
Verona Pharma does not currently pay a dividend.
Verona Pharma does not currently pay a dividend.
Verona Pharma does not currently pay a dividend.
To buy shares in Verona Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Verona Pharma are currently trading at $9.13, giving the company a market capitalisation of £343.7m.
Here are the trading details for Verona Pharma:
We were not able to load our ranking data for Verona Pharma
Shares in Verona Pharma are currently priced at $9.13. At that level they are trading at 1.52% discount to the analyst consensus target price of 0.00.
Analysts covering Verona Pharma currently have a consensus Earnings Per Share (EPS) forecast of -1.5250124884 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Verona Pharma. Over the past six months, the relative strength of its shares against the market has been 15.5%. At the current price of $9.13, shares in Verona Pharma are trading at 38.5% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Verona Pharma.
We were unable to find the directors for Verona Pharma.
Here are the top five shareholders of Verona Pharma based on the size of their shareholding:
